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Cross-Desensitization Among Receptors for Platelet Activating Factor and
Peptide Chemoattractants: Evidence for Independent Regulatory Pathways
Abstract
Cross-desensitization among receptors for peptide chemoattractants have been shown to involve two
independent processes, receptor phosphorylation and inhibition of phospholipase C (PLC) activation.
Receptors for lipid chemoattractants, i.e. platelet activating factor (PAF) and leukotriene B4, did not inhibit
the responses of peptide chemoattractant receptors, suggesting distinct signaling pathways. To examine
cross-desensitization between receptors for lipid and peptide chemoattractants, cDNA encoding the PAF
receptor (PAFR) was co-expressed into RBL-2H3 cells with cDNAs encoding receptors for either
formylated peptides (FR), a product of the fifth component of complement (C5aR) or interleukin-8 A
(IL-8RA). PAFR was homologously phosphorylated and desensitized by PAF, and cross-phosphorylated
and cross-desensitized by fMet-Leu-Phe, C5a, and IL-8. In contrast, the receptors for peptide
chemoattractants were neither cross-phosphorylated nor cross-desensitized by PAF. Staurosporine
blocked cross-phosphorylation and cross-desensitization of the PAFR by peptide chemoattractants.
Truncation of the cytoplasmic tail of PAFR (mPAFR) abolished its homologous and crossphosphorylation. mPAFR was also resistant to cross-desensitization by peptide chemoattractants at the
level of PLC activation. Interestingly, mPAFR mediated a sustained Ca2+ mobilization in response to PAF
and was more active in inducing GTPase activity, phosphoinositide hydrolysis, secretion, and
phospholipase D activation than the wild type PAFR. In contrast to PAFR, stimulation of the mPAFR crossphosphorylated and cross-desensitized responses to IL-8RA. As expected, FR, which is resistant to crossphosphorylation by C5aR and IL-8RA, was not phosphorylated by mPAFR. However, unlike C5aR and
IL-8RA, mPAFR did not inhibit the ability of FR to activate PLC. Blocking Ca2+ influx inhibited mPAFRmediated sustained Ca2+ response, phospholipase D activation and secretion, but not phosphoinositide
hydrolysis and cross-phosphorylation and cross-desensitization of IL-8RA. The data herein suggest that
cross-desensitization of PAFR by peptide chemoattractants is solely due to receptor phosphorylation. The
PAFR and the peptide chemoattractant receptors do not cross-regulate each other at the level of PLC,
suggesting distinct regulatory pathways.
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Cross-desensitization among receptors for peptide
chemoattractants have been shown to involve two independent processes, receptor phosphorylation and inhibition of phospholipase C (PLC) activation. Receptors
for lipid chemoattractants, i.e. platelet activating factor
(PAF) and leukotriene B4, did not inhibit the responses
of peptide chemoattractant receptors, suggesting distinct signaling pathways. To examine cross-desensitization between receptors for lipid and peptide chemoattractants, cDNA encoding the PAF receptor (PAFR) was
co-expressed into RBL-2H3 cells with cDNAs encoding
receptors for either formylated peptides (FR), a product
of the fifth component of complement (C5aR) or interleukin-8 A (IL-8RA). PAFR was homologously phosphorylated and desensitized by PAF, and cross-phosphorylated and cross-desensitized by fMet-Leu-Phe, C5a, and
IL-8. In contrast, the receptors for peptide chemoattractants were neither cross-phosphorylated nor cross-desensitized by PAF. Staurosporine blocked cross-phosphorylation and cross-desensitization of the PAFR by
peptide chemoattractants. Truncation of the cytoplasmic tail of PAFR (mPAFR) abolished its homologous and
cross-phosphorylation. mPAFR was also resistant to
cross-desensitization by peptide chemoattractants at
the level of PLC activation. Interestingly, mPAFR mediated a sustained Ca21 mobilization in response to PAF
and was more active in inducing GTPase activity, phosphoinositide hydrolysis, secretion, and phospholipase D
activation than the wild type PAFR. In contrast to
PAFR, stimulation of the mPAFR cross-phosphorylated
and cross-desensitized responses to IL-8RA. As expected, FR, which is resistant to cross-phosphorylation
by C5aR and IL-8RA, was not phosphorylated by
mPAFR. However, unlike C5aR and IL-8RA, mPAFR did
not inhibit the ability of FR to activate PLC. Blocking
Ca21 influx inhibited mPAFR-mediated sustained Ca21
response, phospholipase D activation and secretion, but
not phosphoinositide hydrolysis and cross-phosphorylation and cross-desensitization of IL-8RA. The data
herein suggest that cross-desensitization of PAFR by
peptide chemoattractants is solely due to receptor phosphorylation. The PAFR and the peptide chemoattractant receptors do not cross-regulate each other at the
level of PLC, suggesting distinct regulatory pathways.
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Phagocytic leukocyte accumulation and activation are regulated in part by chemoattractants released by bacteria or produced by the host. Chemoattractants include products of bacterial protein synthesis (n-formylated peptides, i.e. fMLP),1 a
cleavage product of the fifth component of complement (C5a),
interleukin-8 (IL-8); and the lipid chemoattractants, platelet
activating factor (PAF) and leukotriene B4 (1). Chemoattractants activate leukocytes via cell surface receptors which are
coupled to guanine nucleotide regulatory proteins (G protein)
to activate phospholipase C (PLC) (1–3). Like other members of
this family, chemoattractant receptors become desensitized
upon agonist exposure, resulting in a loss of cellular responsiveness (1, 4). Receptor desensitization has long been categorized as homologous or heterologous, the former being restricted to the agonist-occupied form of the receptor, mediated
by phosphorylation by a receptor-specific kinase (GRK) (4 – 6).
Heterologous desensitization occurs independently of receptor
occupancy by ligand and involves phosphorylation of the receptor by second messenger activated kinases such as protein
kinase C (PKC) (5) or protein kinase A (PKA) (4, 5). Chemoattractant-mediated leukocyte functions have been shown to be
also regulated by a third type of desensitization designated as
“class desensitization” (7, 8). This type of desensitization was
demonstrated among receptors for peptide chemoattractants
(FR, C5aR, and IL-8RA) (9), which utilize the same G protein
(Gia2) to activate a common pool of phospholipase C (PLCb2)
(10, 11). This form of cross-desensitization is less specific than
homologous (involves unoccupied receptor) but more specific
than heterologous desensitization in that only a class of chemoattractant receptors appeared to be involved (8, 9). Studies
in neutrophils also demonstrated that whereas the responses to
the lipid chemoattractants PAF and leukotriene B4 were crossdesensitized by all the peptide chemoattractants, the lipid chemoattractants did not cross-desensitize responses to any of the
peptide chemoattractants (8). This finding further supported
the notion of distinct classes of chemoattractant receptors with
different mechanisms of regulation.
To better define the role of desensitization in the regulation
of the inflammatory response, this laboratory has developed a
model system using a rat basophilic leukemia cell line (RBL2H3) into which multiple chemoattractant receptors can be
expressed and stimulated to elicit cellular responses similar to
those observed in neutrophils (9, 12–14). Using this system,
receptors for peptide chemoattractants were co-expressed and
1
The abbreviations used are: fMLP, formylmethionylleucylphenylalanine; ET-FR, epitope-tagged fMLP receptor; C5a, peptide from the
fifth component of complement; ET-C5aR, epitope-tagged C5a receptor;
IL-8, interleukin-8; ET-IL-8R, epitope-tagged IL-8 receptor; GTPgS,
guanosine 59-39-O-(thio)triphosphate; G protein, GTP-regulatory protein; PAF, platelet activating factor; PAFR, PAF receptor; PLC, phospholipase C; PKC, protein kinase c: FR, formylated peptide; RBL, rat
basophilic leukemia; PMA, phorbol 12-myristate 13-acetate.
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it was recently demonstrated that in addition to receptor phosphorylation and uncoupling of receptors from G protein activation, inhibition of downstream effector activity, presumably
phospholipase C, plays an important role in the class desensitization of peptide chemoattractants (9).
In the present work, the nature of cross-regulation among
peptide and lipid chemoattractant receptors was investigated.
To this end, receptors for PAFR were co-expressed in RBL-2H3
cells with those for FR, C5aR, or IL-8RA to study cross-desensitization among receptor classes. A PAFR mutated to express
a truncated and phosphorylation deficient carboxyl terminus
was also co-expressed with the peptide chemoattractant receptors in these cells. The data presented in this work show that
cross-desensitization of PAFR by the peptide chemoattractants
is a consequence of PAFR cross-phosphorylation and does not
involve inhibitory effects on the activation of PLC.
EXPERIMENTAL PROCEDURES

Materials—[32P]Orthophosphate (8,500 –9,120 Ci/mmol), myo-[23
H]inositol (24.4 Ci/mmol), [3H]myristic acid (11.2 Ci/mmol), [g-32P]GTP
(6000 Ci/mmol), and [35S]GTPgS (1300 Ci/mmol) were purchased from
DuPont NEN. 125I-IL-8 was from Amersham. IL-8 (monocyte derived)
was purchased from Genzyme. Geneticin (G418) and all tissue culture
reagents were purchased from Life Technologies, Inc. Monoclonal
12CA5 antibody, protein G-agarose, and proteases inhibitors were from
Boehringer Manheim. fMLP, Indo-1 acetoxymethyl ester, phorbol 12myristate 13-acetate (PMA), and pluronic acid were from Molecular
Probes. PAF was from Calbiochem. C5a, GDP, GTP, GTPgS, and ATP
were purchased from Sigma. All other reagents were from commercial
sources.
Construction of Epitope-tagged Receptors and PAFR Deletion Mutant—Nucleotides encoding a 9-amino acid epitope sequence (YPYDVPDYA) was inserted between the NH2-terminal initiator methionine and
the second amino acid of each cDNA by polymerase chain reaction as
described previously (12–14). Polymerase chain reaction was also used
to construct a carboxyl-terminal truncated epitope-tagged PAFR mutant. The 59-oligonucleotide corresponding to the epitope-tagged PAFR
was used with a 39-oligonucleotide complementary to amino acids 302–
312 in PAFR. The 39-oligonucleotide was altered to convert amino acids
Thr305 and Ser310 to alanine and glycine, respectively, and a stop codon
following amino acid 312. The resulting polymerase chain reaction
product was cloned into the eukaryotic expression vector pcDNA3 and
the entire receptor was sequenced to confirm the intended mutations
and lack of secondary mutations.
Cell Culture and Transfection—RBL-2H3 cells were maintained as
monolayer cultures in Earle’s modified Eagle’s medium supplemented
with 15% fetal bovine serum, 2 mM glutamine, penicillin (100 units/ml),
and streptomycin (100 mg/ml) (12). Cells (1 3 107/250 ml) were transfected by electroporation with either pRK5 or pcDNA3 vector containing the receptor cDNAs (20 mg). Geneticin-resistant cells were selected
by subculturing the transfected cells in growth medium supplemented
with geneticin (1 mg/ml). Cell surface expression of the receptors were
monitored by fluorescence-activated cell sorter analysis as described
previously (11–13). For the generation of doubly transfected cell lines,
RBL-2H3 cells were transfected with cDNAs encoding both receptors.
Clones were expanded from a single cell and those clones responding to
both ligands were used.
Phosphorylation of the Epitope-tagged (ET) Receptors—Phosphorylation of ET receptors was performed as described previously (10, 12–
14). Briefly, RBL-2H3 cells (3 3 106) expressing a combination of
receptors were subcultured overnight in 60-mm tissue culture dishes.
The following day, the cells were rinsed twice with 5 ml of phosphatefree Dulbecco’s modified Eagle’s medium and incubated in the same
medium supplemented with [32P]orthophosphate (150 mCi/dish) for 90
min in order to metabolically label the intracellular ATP pool. The
labeled cells were then stimulated with or without agonists (IL-8, 100
nM; C5a, 100 nM; or fMLP, 1 mM) for 5–7 min at 37 °C. The phosphorylated receptors were immunoprecipitated from cell lysate with the
12CA5 antibody, analyzed by SDS electrophoresis and visualized by
autoradiography.
GTPgS Binding and GTPase Activity—Cells were treated with appropriate concentrations of stimulants and membranes were prepared
as already described (12). [35S]GTPgS binding and GTPase activity
using 10 –20 mg of membrane preparations were carried out as described previously (14).

Calcium Measurement—Cells (3 3 106) were washed with HEPESbuffered saline and loaded with 1 mM Indo I-AM in the presence of 1 mM
pluronic acid for 30 min at room temperature. The cells were washed
and resuspended in 1.5 ml of buffer. Intracellular calcium increase in
the presence of different ligands at the indicated doses (lowest EC100 for
Ca21 mobilization: fMLP, 100 nM; C5a, 10 nM; IL-8, 10 nM; and PAF, 10
nM) were measured as described (12).
Phosphoinositide Hydrolysis—RBL-2H3 cells were subcultured overnight in 96-well culture plates (5 3 104 cells/well) in inositol-free medium supplemented with 10% dialyzed fetal bovine serum and 1 mCi/ml
[3H]inositol. The cells were then washed with HEPES-buffered saline
containing 10 mM LiCl and 0.1% bovine serum albumin and incubated
in the same buffer with and without stimulants. Reactions were
stopped by adding 200 ml of chloroform, methanol, 4 N HCl (100:200:2).
The generation of [3H]inositol phosphates was determined as reported
(13, 14).
Secretion of b-Hexosaminidase—RBL-2H3 cells were subcultured
overnight in 96-well culture plates (5 3 104 cells/well). Cells were
washed with HEPES-buffered saline containing 0.1% bovine serum
albumin. Cells were then treated with and without agonist and b-hexosaminidase release was assessed as previously reported (12).
Phospholipase D Activation Assay—Transfected RBL-2H3 cells were
subcultured in 24-well plates (2.5 3 105 per well) overnight and labeled
with [3H]myristic acid (2 mCi/well) in HEPES-buffered saline supplemented with 0.1% bovine serum albumin for 90 min. Cells were then
washed and stimulated with an EC100 dose of either PAF (100 nM) or
IL-8 (100 nM) for 5 min. Reactions were terminated by adding 750 ml of
chloroform, methanol, 4 N HCl (100:200:5) to form a monophasic mixture. This was separated into two phases by further addition of chloroform (250 ml) and 0.1 N HCl (250 ml). The upper aqueous phase was
discarded and 10 ml of the lower organic phase was removed and
counted to determine total 3H incorporation. An aliquot (200 ml) was
evaporated to dryness under nitrogen and resuspended in 25 ml of
chloroform:methanol (2:1). Phospholipids were separated by TLC using
chloroform:methanol:acetic acid (65:15:2) as the mobile phase. Unlabeled phosphatidylethanol (500 pmol) was used as a standard. Phosphatidylethanol was visualized with iodine vapor, and the corresponding spot was excised and counted in a liquid scintillation counter to
determine the formation of phosphatidylethanol (8).
RESULTS

Phosphorylation and Immunoprecipitation of Epitope-tagged
Chemoattractant Receptors in RBL-2H3 Cells—RBL-2H3 cells
expressing epitope-tagged FR and PAFR (FR-PAFR), C5aR and
PAFR (C5aR-PAFR), and IL-8RA and PAFR (IL8R-PAFR) were
labeled with 32P, treated with different ligands (100 nM PAF, 1
mM fMLP, 100 nM C5a, or 100 nM IL-8) and cells lysates were
immunoprecipitated with 12CA5 antibody, which specifically
bind to the epitope tag. The identity of the phosphorylated
bands for the respective receptors (FR ; 65 kDa, C5aR ; 45
kDa, IL-8RA ; 70 kDa, and PAFR ; 42 kDa) have been
previously demonstrated by immunoprecipitation of iodinated
and phosphorylated receptors in the presence and absence of
the epitope tag peptide (12–14). As shown in Fig. 1A, PAFR
(;42 kDa) was phosphorylated by PAF (lanes 2, 5, and 8) and
cross-phosphorylated by fMLP (lane 3), C5a (lane 6 and see
next paragraph), and IL-8 (lane 9). FR (;65 kDa) (lane 3),
C5aR (;45 kDa) (lane 6), and IL-8RA (;70 kDa) (lane 9) were
homologously phosphorylated by their respective ligands, but
were resistant to cross-phosphorylation by PAF stimulation.
Since PAFR (;42 kDa) and C5aR (;45 kDa) migrate as
broad overlapping bands in SDS gels, double transfected RBL2H3 cell lines with one native and the other epitope-tagged
receptors were prepared. This allowed clear resolution of the
nature of cross-phosphorylation of these two receptors, as only
the ET receptors are immunoprecipitated with the 12CA5 antibody. In RBL-2H3 cells expressing wild type C5aR and ETPAFR (*C5aR-PAFR) or wild type PAFR and ET-C5aR
(*PAFR-C5aR), activation of the C5aR resulted in cross-phosphorylation of the PAFR but not vice versa (Fig. 1B, lanes 11
and 14 versus lanes 12 and 15).
Effect of Staurosporine on Peptide Chemoattractant-medi-
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FIG. 1. Phosphorylation of epitope-tagged chemoattractant receptors expressed in RBL-2H3 cells. A, 32P-labeled double transfected RBL-2H3 cells (3 3 106/60-mm plate) expressing epitope-tagged
receptors for either fMLP and PAF (FR-PAFR), C5a and PAF (C5aRPAFR), or IL-8 and PAF (IL8R-PAFR) were incubated for 5 min with
(lanes 2, 3, 5, 6, 8 and 9) or without (lanes 1, 4, and 7) stimulants. Cells
were lysed, immunoprecipitated with 12CA5 antibody, and analyzed by
SDS-polyacrylamide gel electrophoresis and autoradiography. This experiment has been repeated 3 times with similar results. B, RBL-2H3
cells expressing either epitope-tagged PAFR and native C5aR (*C5aRPAFR) (lanes 10 –12) or epitope-tagged C5aR and native PAFR (*PAFRC5aR) (lanes 13–15) were stimulated with or without PAF and C5a and
receptor phosphorylation were assessed as described above. This experiment has been repeated twice with similar results.

FIG. 3. Homologous and cross-desensitization of PAFR stimulated [35S]GTPgS binding. Double transfected RBL-2H3 cells expressing C5aR and PAFR were treated with either C5a (100 nM) or PAF
(100 nM) for 5 min, membranes were prepared and assayed for agoniststimulated [35S]GTPgS binding. The data shown are the means of three
different experiments performed in triplicate. The values are represented as percentage of maximum stimulation, which is defined as the
maximal increase above basal [35S]GTPgS bound to control membranes
(untreated cells) after 10 min of reaction. Basal activities were 0.17 6
0.02 pmol of [35S]GTPgS bound/mg of protein. Maximum net stimulation was 0.114 6 0.006 (C5a) and 0.122 6 0.008 (PAF) pmol of
[35S]GTPgS bound/mg of protein for untreated cells. *, p , 0.05 and **,
p , 0.01 compared to control.
TABLE I
Cross-desensitization of PAFR-mediated Ca21 mobilization by
fMLP, C5a, and IL-8
RBL-2H3 cells (3 3 106 cells/assay) expressing FR-PAFR, C5aRPAFR, or IL8R-PAFR were loaded with Indo-1 and stimulated with
either fMLP (100 nM), PAF (10 nM), C5a (10 nM), or IL-8 (10 nM). Cells
were rechallenged 3 min later with a second dose of ligand and peak
intracellular Ca21 mobilization was determined. Values are represented as percentage of inhibition (cross-desensitization) of the Ca21
response elicited in the absence of pretreatment (PAF, 582 6 19 nM;
fMLP, 628 6 32 nM; C5a, 684 6 16 nM, IL-8, 530 6 21 nM). Data are the
mean 6 S.E. of three different experiments.
Cells

FR-PAFR
C5aR-PAFR
IL8R-PAFR
FIG. 2. Effect of staurosporine on fMLP, IL-8, and PMA-induced PAFR cross-phosphorylation. 32P-Labeled double transfected RBL-2H3 cells (3 3 106/60-mm plate) expressing either FR-PAFR
or IL8R-PAFR were preincubated for 3 min with (lanes 3, 5, 7, 10, 12,
and 14) or without (lanes 1, 2, 4, 6, 8, 9, 11, and 13) staurosporine (100
nM) and stimulated with fMLP, IL-8, or PMA for 5 min. Cells were
lysed, immunoprecipitated with 12CA5 antibody, and analyzed by SDSpolyacrylamide gel electrophoresis and autoradiography. The results
are from one of two representative experiments.

ated Cross-phosphorylation of PAFR—The involvement of PKC
on fMLP and IL-8-mediated cross-phosphorylation of PAFR
was studied. 32P-Labeled RBL-2H3 cells expressing FR-PAFR
and IL8R-PAFR were preincubated with or without the PKC
inhibitor staurosporine (100 nM) for 3 min and then stimulated
with PAF (100 nM), fMLP (1 mM), IL-8 (100 nM), or PMA (100
nM). Whereas PAF-induced phosphorylation of ET-PAFR was
not affected by staurosporine (Fig. 2, lanes 2, 9, 3, and 10),
PAFR cross-phosphorylation by either fMLP or IL-8 were
markedly inhibited (lanes 4, 5, 11, and 12). PMA-induced phosphorylation of PAFR was also blocked by staurosporine (lanes
6, 7, 13, and 14).
GTPgS Binding in Cross-phosphorylated Membranes—To
determine the effect of cross-phosphorylation on PAFR function, agonist-stimulated [35S]GTPgS binding was measured in
membranes prepared from double transfected RBL-2H3 cells
expressing PAFR and C5aR, and pretreated with either PAF
(100 nM) or C5a (100 nM). As shown in Fig. 3, pretreatment of
cells with either PAF or C5a resulted in homologous desensi-
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a
b

Agonists

% Cross-desensitization

fMLP 3 PAF
PAF 3 fMLP
C5a 3 PAF
PAF 3 C5a
IL-8 3 PAF
PAF 3 IL-8

47 6 12.3a
26 6 7
80 6 7.9b
3 6 2.7
31 6 14a
1 6 3.7

p , 0.05.
p , 0.01.

tization (;70%) of agonist-induced [35S]GTPgS binding to
membranes. Membranes from cells pretreated with C5a
showed a ;50% decrease in PAF-stimulated [35S]GTPgS binding. Only a ;13% desensitization was observed for C5a-stimulation in cells pretreated with PAF.
Cross-desensitization of Receptor-induced Ca21 Mobilization—Ca21 mobilization was measured to further determine
the relationship between receptor cross-phosphorylation and
cross-desensitization. Ca21 mobilization in response to an
EC100 dose of fMLP (100 nM), C5a (10 nM), IL-8 (10 nM), or PAF
(10 nM) was homologously desensitized by a first dose of the
same ligand (data not shown, see Refs. 12–14). PAF-induced
Ca21 mobilization was cross-desensitized by pretreatment of
the cells with a first dose of fMLP, C5a, or IL-8 (Table I). In
contrast, pretreatment of the cells with an EC100 first dose of
PAF had no effect on Ca21 mobilization induced by any of the
peptide chemoattractants (Table I).
Co-expression and Characterization of a Mutant PAFR in
RBL-2H3 Cells—In order to assess the role of phosphorylation
in the cross-desensitization of PAFR by the peptide chemoattractant receptors, a phosphorylation deficient PAFR mutant
(mPAFR) was constructed (Table II). The mPAFR was cotransfected into RBL-2H3 cells with pcDNA3 plasmid containing
either FR or IL-8RA. Stable transfectants were generated and
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TABLE II
Amino acid sequences of the carboxyl-terminal tails of the wild type PAF receptor (PAFR) and the mutant PAF receptor (mPAFR) construct
Bold and underlined serines and threonines residues are potential phosphorylation sites of the wild type receptor which have been either
removed by deletion or substituted by alanine or glycine in the mutant PAF receptor.

298
342
2
2
C-tail PAFR KKFRKHLTEKFYSMRSSRKCSRATTDTVTEVVVPFNQIPGNSLKN
mPAFR KKFRKHLAEKFYGMR

single cell cloning was utilized to isolate double transfectants.
Competition binding using [3H]WEB 2086 and Scatchard analysis of wild type versus the mutant indicated that deletion of
the carboxyl tail had no significant effect on the affinity of the
receptor (Kd ;10 and ;19 nM for wild type and mutant PAFR,
respectively). Clones expressing similar receptor numbers
(2.8 –3.3 3 103 receptors/cell) were utilized to determine the
functional properties of the mutant PAFR versus the wild type
receptor.
Time course of both PAFR- and mPAFR-mediated [35S]
GTPgS binding in membranes were similar, with half-maximal
binding at ;4 min (data not shown). Maximum binding after 20
min of reactions were 0.13.6 0.02 and 0.12 6 0.016 pmol of
[35S]GTPgS bound/mg of protein for mPAFR and PAFR, respectively. However, GTPase activity in membranes (Fig. 4A), phosphoinositide hydrolysis (Fig. 4B), and b-hexosaminidase release (Fig. 4C) in intact cells revealed that mPAFR was more
active than the wild type PAFR in mediating cellular responses. Peaks of intracellular Ca21 mobilization in response
to PAF (10 nM) were similar for both, wild type (598 nM) and
mutant PAFR (624 nM) (Fig. 4D). However, a more sustained
response was obtained with mPAFR as compared to the wild
type receptor (Fig. 4D).
The ability of mPAFR and wild type PAFR to stimulate PLD
activation was also determined and compared to that of IL-8RA
in RBL-2H3 cells co-expressing IL-8RA and either PAFR
(IL8R-PAFR) or mPAFR (IL8R-mPAFR). As shown in Fig. 5,
IL-8-induced PLD activation was similar in both cell lines,
0.61 6 0.014- and 0.53 6 0.04-fold over basal, for IL8R-PAFR
and IL8R-mPAFR cells, respectively (Fig. 5). In contrast, PAFinduced PLD activity was ;5-fold greater in cells expressing
IL8R-mPAFR (1.43 6 0.07) than IL8R-PAFR (0.26 6 0.02).
Cross-phosphorylation of mPAFR by fMLP and IL-8 —32PLabeled RBL-2H3 cells co-expressing the epitope-tagged
mPAFR and either FR (FR-mPAFR), or IL-8RA (IL8R-mPAFR)
were treated with different ligands (PAF, 100 nM; fMLP, 1 mM;
or IL-8, 100 nM) and immunoprecipitated with 12CA5 antibody.
As shown in Fig. 6, mPAFR (;42 kDa) was resistant to phosphorylation by PAF (lanes 2 and 5) and cross-phosphorylation
by either fMLP (lane 3) or IL-8 (lane 6). FR (;65 kDa) (lane 3)
and IL-8RA (;70 kDa) (lane 6) were homologously phosphorylated by fMLP and IL-8, respectively. While FR was resistant to
cross-phosphorylation, stimulation of the mutant PAFR resulted in IL-8RA cross-phosphorylation (lane 5). The extent of
mPAFR-mediated cross-phosphorylation of IL-8RA was similar
to the extent of phosphorylation of IL-8RA by PMA (Fig. 2, lane
13). In addition, IL-8RA cross-phosphorylation by mPAFR was
inhibited by staurosporine (100 nM) (data not shown).
Effect of mPAFR-mediated Cross-phosphorylation of IL-8RA
on Receptor/G Protein Coupling—The ability of IL-8RA to
stimulate [35S]GTPgS binding in membranes from cells expressing IL8-RA and mPAFR was determined. As shown in Fig.
7, pretreatment of the cells with IL-8 caused ;67% homologous
desensitization of IL-8-induced response compared to control
(untreated cells). There was no effect on mPAFR. Membranes
from cells pretreated with PAF (100 nM) was resistant to homologous desensitization but showed a ;50% decrease of the
response to IL-8RA. Simultaneous pretreatment of the cells

FIG. 4. Functional characterization of phosphorylation-deficient PAF receptor mutant (mPAFR) versus PAFR. A, for GTPase
activity, membranes were prepared from RBL-2H3 cells expressing
either the mutant PAFR or the wild type PAFR and assayed at different
concentrations of PAF. Data shown are representative of one of three
experiments performed in triplicate. B, for the generation of inositol
phosphates, cells were cultured overnight in the presence of [3H]inositol
(1 mCi/ml). Cells were preincubated (10 min, 37 °C) with a HEPESbuffered saline containing 10 mM LiCl in a total volume of 200 ml and
stimulated with different concentrations of PAF for 10 min. [3H]Inositol
phosphates release was determined. Data are represented as fold stimulation over basal, which was 475 6 30 cpm for mPAFR and 347 6 49
for PAFR. The experiment was repeated three times with similar results. C, cells were treated with different concentrations of PAF and
b-hexosaminidase release in the medium was assessed. Data are represented as percentage of total which were 0.56 6 0.003 (PAFR) and
0.47 6 0.006 (mPAFR). The experiment was repeated twice with similar
results. D, RBL-2H3 cells (3 3 106 cells/assay) were loaded with Indo-1
and PAF (10 nM)-induced Ca21 mobilization was measured.

with staurosporine (100 nM) blocked significantly both the homologous (;40%) and cross- (66%) desensitization of IL-8RAinduced [35S]GTPgS binding.
Cross-desensitization of mPAFR-induced Ca21 Mobilization
by fMLP and IL-8 —It was determined whether the Ca21 mobilization in response to PAF was cross-desensitized by either
fMLP or IL-8 in RBL-2H3 cells expressing FR-mPAFR or IL8RmPAFR. PAF-induced Ca21 mobilization was resistant to
cross-desensitization by pretreatment of the cells with either
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FIG. 5. PAFR- and mPAFR-mediated PLD activation. RBL-2H3
cells expressing IL8R-PAFR or IL8R-mPAFR were labeled with
[3H]myristic acid and stimulated with or without agonists. Formation of
phosphatidylethanol (PtdEtOH) was measured as described under “Experimental Procedures.” Data are represented as fold increase over
basal and are from one of three representative experiments. Basal
values were 0.99 6 0.08 (IL8R-PAFR) and 0.97 6 0.09 (IL8R-mPAFR).
Similar results were obtained in three separate experiments. *, p , 0.01
as compared to mPAFR.

28721

FIG. 7. Cross-desensitization of IL-8RA-stimulated [35S]GTPgS
binding by mPAFR. Double transfected RBL-2H3 cells expressing
IL-8RA and mPAFR were treated with either IL-8 (100 nM) or PAF (100
nM) in the presence or absence of staurosporine (100 mM) for 5 min,
membranes were prepared and assayed for agonist-stimulated
[35S]GTPgS binding. The data shown are the means of three different
experiments performed in triplicate. The values are represented as
percentage of maximum stimulation, which is defined as the maximal
increase above basal [35S]GTPgS bound to control membranes (untreated cells) after 10 min of reaction. Basal activities were 0.2 6 0.015 pmol
of [35S]GTPgS bound/mg of protein. Maximum net stimulation were
0.16 6 0.07 (IL-8) and 0.14 6 0.03 (PAF) pmol of [35S]GTPgS bound/mg
of protein for untreated cells. *, p , 0.05; and **, p , 0.01 compared to
control.
TABLE III
Cross-desensitization of Ca21 mobilization in cells expressing
FR-mPAFR and IL8R-mPAFR
RBL-2H3 cells (3 3 106 cells/assay) expressing FR-mPAFR or IL8RmPAFR and, for comparison, cells expressing FR-C5aR were loaded
with Indo-1 and stimulated with PAF (10 nM), fMLP (100 nM), IL-8 (10
nM), or C5a (10 nM). Cells were rechallenged 3 min later with a second
dose of the indicated ligand and peak of intracellular Ca21 mobilization
was determined. Values are represented as percentage of inhibition
(cross-desensitization) of the Ca21 response elicited in the absence of
pretreatment (PAF, 595 6 41 nM, fMLP, 532 6 28 nM, IL-8, 533 6 17
nM, and C5a, 487 6 17 nM). Data are the means 6 S.E. of three different
experiments.
Cells

FR-mPAFR
FIG. 6. Cross-phosphorylation of mPAFR by FR and IL-8R.
RBL-2H3 cells co-expressing FR-mPAFR or IL8R-mPAFR were 32Plabeled and stimulated for 5 min with (lanes 2, 3, 5, and 6) or without
(lanes 1 and 4) agonists. Receptor phosphorylation was assessed as
described in the legend to Fig. 1. This experiment has been repeated
three times with similar results.

fMLP or IL-8 (Table III). However, while pretreatment of cells
with a first dose of PAF had no effect on fMLP-induced Ca21
mobilization, response to IL-8 was desensitized by ;60% (Table III). In contrast to PAFR and mPAFR, Ca21 mobilization in
response to FR was cross-desensitized by both C5aR (Table III)
and IL-8RA (data not shown) despite FR resistance to crossphosphorylation (9).
Effect of Extracellular Calcium on mPAFR-mediated Signal
Transduction—The effect of Ca21 influx on mPAFR-mediated
cellular responses as well as cross-phosphorylation and crossdesensitization of IL-8RA was assessed using the cation chelator EGTA to block extracellular calcium influx. EGTA had no
effect in mPAFR-mediated PI hydrolysis (Fig. 8A) However,
EGTA blocked mPAFR-induced PLD activation (Fig. 8B), secretion (Fig. 8C), and the sustained Ca21 mobilization in response to PAF (Fig. 8, D and E). EGTA had no significant effect
on mPAFR-mediated cross-desensitization of IL-8RA induced
Ca21 response (Fig. 8, D and E) and cross-phosphorylation of
IL-8RA (Fig. 9).
DISCUSSION

Previous studies have indicated that chemoattractant receptors trigger cellular activities by two related but distinguishable pathways. The first via the heterotrimeric G protein-

IL8R-mPAFR
FR-C5aR
a

Agonists

% Cross-desensitization

fMLP 3 PAF
PAF 3 fMLP
IL-8 3 PAF
PAF 3 IL-8
fMLP 3 C5a
C5a 3 fMLP

7 6 0.3
2 6 0.26
28 6 1
61 6 4.7a
60 6 9a
50 6 10a

p , 0.05.

mediated activation of PLC, the second via activation of PLD
(1). Whereas all chemoattractants (peptides and lipids) initiate
the former equally well, peptide chemoattractants are far more
active in stimulating PLD, which is required for the cytotoxic
actions of phagocytes (i.e. respiratory burst and exocytosis) (1,
15–17). While chemoattractant receptors for peptides and lipids all activate PLC via G proteins, the difference in their
regulation has been suggested to be a consequence of their
utilizing different G proteins and PLC isozymes (10, 18 –20).
This laboratory has been investigating the regulation and
cross-regulation of leukocyte chemoattractant receptors and
has developed cellular models allowing genetic analysis of receptor functions. Using these strategies, it has been shown that
peptide chemoattractant receptor desensitization occurs at two
sites, the first involving receptor phosphorylation leading to
diminished G protein activation. The second involves the inhibition of the activation of PLC (9). Data in neutrophils demonstrated differences in cross-regulation among receptors for peptide versus lipid chemoattractants (8), suggesting disparate
signaling and regulatory pathways. However, the molecular
mechanism underlying this phenomenon of cross-regulation
among different classes of receptors has not been studied.
A goal of this study was to better define the regulation and

28722

Cross-regulation of Chemoattractant Receptors

FIG. 8. Effect of EGTA on mPAFR-mediated cellular responses. A, inositol phosphates (IP) generation; B, phospholipase D activation; C,
b-hexosaminidase release; and D and E, Ca21 mobilization in the presence and absence of EGTA (5 mM) were determined as described in the legend
to Fig. 4 and Table I. The experiments were repeated twice with similar results.

FIG. 9. Effect of EGTA on mPAFR-mediated cross-phosphorylation of IL-8RA. RBL-2H3 cells expressing IL8R-mPAFR were
32
P-labeled and stimulated for 5 min with (lanes 3– 6) or without (lanes
1 and 2) agonists in the presence (lanes 2, 4, and 6) and absence (lanes
1, 3, and 5) of 5 mM EGTA. Receptor phosphorylation was assessed as
described in the legend to Fig. 1. This experiment has been repeated
three times with similar results.

cross-regulation of the PAF receptor. The approach undertaken
was to co-express, in RBL-2H3 cells, PAFR, or a phosphorylation deficient PAFR with the receptors for fMLP, C5a, or IL-8.
The data presented herein demonstrate that PAFR was crossphosphorylated upon activation of all three peptide chemoattractant receptors (Fig. 1) and that this correlated with the
cross-desensitization of the receptor as measured by GTPgS
binding in membranes (Fig. 3) and Ca21 mobilization in intact
cells (Table I). The results suggest a role for phosphorylation
mediated by PKC in PAFR cross-desensitization since both
peptide chemoattractants- and PMA-mediated phosphorylation were inhibited by the PKC inhibitor staurosporine (Fig. 2).

Like many members of the G-protein coupled receptor family, PAFR possesses a serine/threonine-rich cytoplasmic tail (5
serines and 6 threonines), which contains potential sites for
agonist-dependent and -independent phosphorylation (21, 22).
The carboxyl terminus plays a key role in the desensitization
and regulation of several G-protein-coupled receptors (23–28).
Elimination of phosphorylatable residues in the carboxyl terminus of the guinea pig PAFR, by either alanine substitution or
truncation, diminished agonist-induced receptor desensitization (29). Based on these observations and, in an attempt to
assess the role of receptor phosphorylation on PAFR regulation, a phosphorylation deficient human PAFR mutant containing a truncated carboxyl terminus was constructed (Table II).
When co-expressed with FR and IL-8RA, this mutant was
resistant to cross-phosphorylation and, importantly, cross-desensitization both at the level of G protein activation and Ca21
mobilization (Fig. 6 and Table III). This indicates that, unlike
the peptide chemoattractant receptors, cross-desensitization of
PAFR by the peptide chemoattractants is solely due to phosphorylation of the receptor by a PKC-dependent process and
does not involve the direct downstream inhibition of PLC activation. This latter observation further supports the concept of
class desensitization as a form of cellular regulation involving
group of receptors sharing similar activation pathways (7–9)
and suggests that receptors for lipid chemoattractants are regulated differently.
Studies in intact neutrophils indicated that whereas peptide
chemoattractants desensitized the responses to lipid chemoat-
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tractants, the reverse was not true (8). The studies presented
here provide a molecular basis for this observation. RBL-2H3
cells expressing PAFR and FR, C5aR, or IL-8RA showed that
PAFR was readily phosphorylated and desensitized by FR,
C5aR, and IL-8RA but was incapable of phosphorylating or
desensitizing the peptide chemoattractant receptors. This is of
interest since the PAFR clearly activated PLC and undergo
phosphorylation by both PKC-dependent and PKC-independent processes (13). Several explanations were considered. First,
the level of PLC activation might be insufficient to generate
enough PKC activity for cross-phosphorylation. Second, crossphosphorylation may be a consequence of PLD activation and
PAFR is a poor PLD activator (1). Finally the type of PKC or
other second messenger-dependent kinase activated by PAFR
may be unable to phosphorylate peptide chemoattractant receptors. The development of the mPAFR allowed these questions to be addressed. mPAFR displayed striking differences
when compared to the PAFR in stimulating far greater activation of PLC as well as sustained Ca21 influx and activation of
PLD (Figs. 4 and 5). The mechanism for this enhanced receptor
activity appears to be a consequence of greater turnover of G
proteins apparently due to resistance of the receptor to undergo
phosphorylation and, thus, desensitization. The mPAFR is instructive in that it shows that the cytoplasmic tail of the PAFR,
presumably through phosphorylation, regulates the extent of G
protein activation mediated by a single dose of ligand. It moreover shows that greater activation of G proteins by the receptor
allows for the opening of a channel allowing Ca21 influx (30).
When this was blocked by EGTA, PLD activation did not occur,
demonstrating the requirement of Ca21 influx for the activation of this enzyme. Stimulation of the mPAFR (Fig. 6), unlike
PAFR (Fig. 1), led to cross-phosphorylation of IL-8RA. This
cross-phosphorylation was dependent on PLC but not on PLD
activation, since EGTA which blocked the latter, but had no
effect on IL-8RA phosphorylation (Fig. 9). This suggests that
the level of PLC activation by PAFR determines its ability to
cross-phosphorylate and cross-desensitize peptide chemoattractant receptors. Under normal conditions, given the level of
receptors expressed in neutrophils or in the studies here, the
PAFR apparently does not activate enough PLC to mediate
cross-phosphorylation.
The extent of mPAFR-mediated cross-phosphorylation of IL8RA was minor as compared to the extent of cross-phosphorylation of wild type PAFR by IL-8RA (Figs. 6 and 9 versus
Figs. 1 and 2). Nonetheless this phosphorylation of the IL-8RA
was significant in that it resulted in a ;50 and 61% crossdesensitization of IL-8RA-induced GTPgS binding and intracellular Ca21 mobilization, respectively. Furthermore, staurosporine blocked both the cross-phosphorylation and crossdesensitization of IL-8RA indicating a role for PKC in this
process. It has been shown that homologous phosphorylation of
rhodopsin, b-adrenergic receptors, and muscarinic receptors by
receptor specific kinases (rhodopsin kinase and b-adrenergic
receptor kinases) do not cause receptor desensitization unless
specific protein such as arrestin or b-arrestin are present (35–
38). However, heterologous phosphorylation of these receptors
by PKC and PKA (although to lower extents than homologous)
caused 35–50% inhibition of receptor/G protein coupling (4, 5,
37). This suggest that receptor desensitization at the level of
receptor/G protein coupling for a number of receptors, including those for IL-8, may be due to the phosphorylation of a small
number of specific residue(s) involved in such interaction.
Another finding of note is that neither the PAFR nor the
mPAFR at the dose tested (EC100 versus EC100) generated the
signal which results in downstream inhibition of PLC activation by peptide chemoattractant receptors, since neither PAFR
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nor mPAFR inhibited Ca21 mobilization by FR (Tables I and
III). Thus, not only are PAFR not subject to regulation at the
level of PLC activation by peptide chemoattractant receptors,
they do not produce the signal(s) sufficient to mediate this
activity. Since mPAFR mediates substantial activation of PLC,
Ca21 influx, and PLD, it can be presumed that second messengers produced by these pathways are not sufficient to produce
class-desensitization of peptide chemoattractants. More likely,
a component(s) unique to the peptide chemoattractant receptors pathways is involved in its susceptibility to regulation of
PLC activation. The nature of this signal(s) or second messenger(s) remains to be determined. A clue may be found in the
differences in G proteins and PLCs used by PAFR versus peptide chemoattractant receptors. Whereas the latter interact
preferentially with Gi (pertussis toxin (Ptx)-sensitive) to stimulate PLCb2 via Gbg (10, 11, 19), PAFR is thought to couple to
members of the Gq family (Ptx-insensitive) of G proteins to
activate PLCg via Ga (13, 19, 31–34). Thus the Gbg of Gi may
be a site for cross-regulation of chemoattractant receptors for
peptide.
In all, these studies point out the utility of cellular and
genetic models to elucidate the complexities of receptor regulation and cross-regulation. While all the chemoattractant receptors studied are effective mediators of directed cellular migration, they are likely to play different physiological roles in
other aspects of phagocyte regulation. The PAFR clearly is
subject to different regulatory processes than the peptide chemoattractant receptors as reflected in its resistance to inhibition at the level of PLC activation and its inability to affect PLC
activation by the peptide chemoattractant receptors. These
data are likely to reflect the distinct usage of G proteins and
PLC isozymes by the different groups of receptors and indicates
that receptor cross-regulation involves mechanisms beyond receptor phosphorylation.
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